Streptococcus pneumoniae serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy?
S. pneumoniae serotypes responsible for pneumococcal disease differ with respect to disease severity, invasiveness, antimicrobial susceptibility, geographies, immunization history, age groups, and with time. Although PCVs have blunted the pneumococcal disease burden, they are plagued with numerous c...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2461844 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849763502003060736 |
|---|---|
| author | Priya Dhawale Sanket Shah Kaushal Sharma Deepa Sikriwal Varnik Kumar Arnabjyoti Bhagawati Sakshi Dhar Pratiksha Shetty Syed Ahmed |
| author_facet | Priya Dhawale Sanket Shah Kaushal Sharma Deepa Sikriwal Varnik Kumar Arnabjyoti Bhagawati Sakshi Dhar Pratiksha Shetty Syed Ahmed |
| author_sort | Priya Dhawale |
| collection | DOAJ |
| description | S. pneumoniae serotypes responsible for pneumococcal disease differ with respect to disease severity, invasiveness, antimicrobial susceptibility, geographies, immunization history, age groups, and with time. Although PCVs have blunted the pneumococcal disease burden, they are plagued with numerous challenges, especially the emergence of NVTs. In this review, we show that there are diverse serotypes, especially NVTs, responsible for causing pneumococcal diseases in LMICs of South Asia across different studies conducted between 2012 and 2024. We propose that pharmaceutical/biotech companies should tailor/customize the PCVs as per the region-specific serotype prevalence based on surveillance data. Furthermore, protein-based vaccines, or WCVs, have been explored and can serve as viable alternatives to address the limitations associated with PCVs. However, robust studies are warranted in different geographies to demonstrate its efficacy and safety in clinical trials as well as the real-world effectiveness of these promising candidates. |
| format | Article |
| id | doaj-art-b205b3bc72274e6cb4af1ead08d208fd |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-b205b3bc72274e6cb4af1ead08d208fd2025-08-20T03:05:22ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2025.2461844Streptococcus pneumoniae serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy?Priya Dhawale0Sanket Shah1Kaushal Sharma2Deepa Sikriwal3Varnik Kumar4Arnabjyoti Bhagawati5Sakshi Dhar6Pratiksha Shetty7Syed Ahmed8Global Business Development, Techinvention Lifecare Private Limited, Mumbai, IndiaStrategic Medical Affairs, Techinvention Lifecare Private Limited, Mumbai, IndiaStrategic Projects, Techinvention Lifecare Private Limited, Mumbai, IndiaResearch and Development, Techinvention Lifecare Private Limited, Mumbai, IndiaResearch and Development, Techinvention Lifecare Private Limited, Mumbai, IndiaResearch and Development, Techinvention Lifecare Private Limited, Mumbai, IndiaResearch and Development, Techinvention Lifecare Private Limited, Mumbai, IndiaRegulatory Affairs, Techinvention Lifecare Private Limited, Mumbai, IndiaBusiness Development and Strategy, Techinvention Lifecare Private Limited, Mumbai, IndiaS. pneumoniae serotypes responsible for pneumococcal disease differ with respect to disease severity, invasiveness, antimicrobial susceptibility, geographies, immunization history, age groups, and with time. Although PCVs have blunted the pneumococcal disease burden, they are plagued with numerous challenges, especially the emergence of NVTs. In this review, we show that there are diverse serotypes, especially NVTs, responsible for causing pneumococcal diseases in LMICs of South Asia across different studies conducted between 2012 and 2024. We propose that pharmaceutical/biotech companies should tailor/customize the PCVs as per the region-specific serotype prevalence based on surveillance data. Furthermore, protein-based vaccines, or WCVs, have been explored and can serve as viable alternatives to address the limitations associated with PCVs. However, robust studies are warranted in different geographies to demonstrate its efficacy and safety in clinical trials as well as the real-world effectiveness of these promising candidates.https://www.tandfonline.com/doi/10.1080/21645515.2025.2461844Streptococcus pneumoniaeinvasive pneumococcal diseasepneumococcal vaccinesantimicrobial resistanceSouth Asia |
| spellingShingle | Priya Dhawale Sanket Shah Kaushal Sharma Deepa Sikriwal Varnik Kumar Arnabjyoti Bhagawati Sakshi Dhar Pratiksha Shetty Syed Ahmed Streptococcus pneumoniae serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy? Human Vaccines & Immunotherapeutics Streptococcus pneumoniae invasive pneumococcal disease pneumococcal vaccines antimicrobial resistance South Asia |
| title | Streptococcus pneumoniae serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy? |
| title_full | Streptococcus pneumoniae serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy? |
| title_fullStr | Streptococcus pneumoniae serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy? |
| title_full_unstemmed | Streptococcus pneumoniae serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy? |
| title_short | Streptococcus pneumoniae serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy? |
| title_sort | streptococcus pneumoniae serotype distribution in low and middle income countries of south asia do we need to revisit the pneumococcal vaccine strategy |
| topic | Streptococcus pneumoniae invasive pneumococcal disease pneumococcal vaccines antimicrobial resistance South Asia |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2025.2461844 |
| work_keys_str_mv | AT priyadhawale streptococcuspneumoniaeserotypedistributioninlowandmiddleincomecountriesofsouthasiadoweneedtorevisitthepneumococcalvaccinestrategy AT sanketshah streptococcuspneumoniaeserotypedistributioninlowandmiddleincomecountriesofsouthasiadoweneedtorevisitthepneumococcalvaccinestrategy AT kaushalsharma streptococcuspneumoniaeserotypedistributioninlowandmiddleincomecountriesofsouthasiadoweneedtorevisitthepneumococcalvaccinestrategy AT deepasikriwal streptococcuspneumoniaeserotypedistributioninlowandmiddleincomecountriesofsouthasiadoweneedtorevisitthepneumococcalvaccinestrategy AT varnikkumar streptococcuspneumoniaeserotypedistributioninlowandmiddleincomecountriesofsouthasiadoweneedtorevisitthepneumococcalvaccinestrategy AT arnabjyotibhagawati streptococcuspneumoniaeserotypedistributioninlowandmiddleincomecountriesofsouthasiadoweneedtorevisitthepneumococcalvaccinestrategy AT sakshidhar streptococcuspneumoniaeserotypedistributioninlowandmiddleincomecountriesofsouthasiadoweneedtorevisitthepneumococcalvaccinestrategy AT pratikshashetty streptococcuspneumoniaeserotypedistributioninlowandmiddleincomecountriesofsouthasiadoweneedtorevisitthepneumococcalvaccinestrategy AT syedahmed streptococcuspneumoniaeserotypedistributioninlowandmiddleincomecountriesofsouthasiadoweneedtorevisitthepneumococcalvaccinestrategy |